作者
Tarik Asselah,Vladimir Chulanov,Pietro Lampertico,Jacobus J. Bosch,Adrian Streinu‐Cercel,Victor Pântea,Ştefan Lazăr,Gheorghe Plăcintă,George Sebastian Gherlan,Pavel Bogomolov,T.V. Stepanova,Viatcheslav Morozov,V. Е. Syutkin,Olga Sagalova,Dmitry Manuilov,Renée-Claude Mercier,Lei Ye,Ben L. Da,Grace M. Chee,Audrey H. Lau,Anu Osinusi,Marc Bourlière,Vlad Ratziu,Fabien Zoulim,Marie‐Noëlle Hilleret,Fabien Zoulim
摘要
In a phase 3 trial, bulevirtide monotherapy led to a virologic response in patients with chronic hepatitis D. Pegylated interferon (peginterferon) alfa-2a is recommended by guidelines as an off-label treatment for this disease. The role of combination therapy with bulevirtide and peginterferon alfa-2a, particularly with regard to finite treatment, is unclear.
不配.
含蓄的明雪
彭于彦祖
苏卿
薰硝壤
哎嘿
pcr163
吃不饱星球球长
暮霭沉沉
甜甜玫瑰
互助遵法尚德
iNk
Yziii
嗯哼
Henry
从容芮
oceanao
寻道图强
HEIKU
Jun
皖公网安备34019202002308
